IngredientsN-coumaroyldopamine is an amide derivative of dopamine and p-coumaric acid. Its systematic IUPAC name is (2E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide. Its CAS registry number is 103188-46-1, and its molecular formula is C17H17NO4, with a molar mass of approximately 299.32 g/mol. It is registered in the National Institutes of Health's PubChem database under Compound Identifier (CID) 11630793.
It belongs to a large family of plant phenolamides, comprising compounds derived from the association of phenolic acids with aliphatic or aromatic amines. More specifically, they are classified as hydroxycinnamic acid amides (HCAAs), a diverse group of specialized plant phenylpropanoid metabolites that are involved in maintaining plant tolerance to abiotic and biotic stress.
N-coumaroyldopamine and N-caffeoyldopamine are clovamide-type phenylpropenoic acid amides found in Theobroma cacao. Clovamide is structurally related to some β-adrenergic ligands (dobutamine, denopamine), and clovamide derivatives N-coumaroyldopamine and N-caffeoyldopamine (also found in cocoa) have been shown to be potent β2-adrenoceptor agonists.
N-coumaroyldopamine is a solid powder, white or light yellow in color, soluble in water and ethanol, with solubility also in organic solvents and acidic media. The compound has poor stability to air and light and is easily oxidized. The compound's structural backbone combines the catechol moiety of dopamine with a hydroxycinnamic acid (p-coumaric acid) side chain connected via an amide bond, giving rise to its dual pharmacophoric character.
N-caffeoyldopamine (the closely related parent compound) is a phytochemical found in various plants, including cocoa (Theobroma cacao L.). N-coumaroyldopamine shares this botanical origin. In addition to Theobroma cacao, those compounds are also synthesized, among other things, by Trifolium pallidum clover and Trifolium pratense (red clover), and species of the Capsicum genus.
The name "clovamide" directly derives from red clover (Trifolium pratense L.), being the first identified source of this compound. It was identified for the first time by Yoshihara, Yoshikawa, Sakamura, and Sakuma (1974) in the red clover, and only later was described in cocoa. Sanbongi et al. (1998) identified for the first time clovamide and its derivative deoxyclovamide in cocoa liquor. More recently, clovamide was identified also in cocoa beans (both fermented unroasted cocoa beans and roasted nibs) and hulls.
In the human diet, clovamides are mainly present in chocolate and other cocoa-containing products. Beyond cocoa and clover, the hydroxycinnamic acid amides (HCAAs) are a diverse group of plant-specialized phenylpropanoid metabolites distributed widely in the plant kingdom and are known to be involved in tolerance to abiotic and biotic stress.
Clovamide, a hydroxycinnamic acid amide (HCAA) metabolite, has been described as an important resistance factor in cacao (Theobroma cacao) against pathogens in the genus Phytophthora, an oomycete genus comprised of over 100 species, many of which are globally important plant pathogens with broad host ranges. This confirms that N-coumaroyldopamine and related compounds serve ecological and defensive roles in their plant hosts, rather than existing primarily as nutritionally targeted compounds.
Despite a growing interest in the biological activity of natural polyphenolic substances, studies on the properties of clovamide and related compounds, their significance as bioactive components of the diet, as well as their effects on human health are a relatively new research trend. This means that N-coumaroyldopamine, as an isolated phytochemical entity, does not possess a documented traditional-use history as a defined ingredient. Instead, its historical presence in food and medicine is mediated through the plant sources in which it occurs.
Cocoa (Theobroma cacao), one of the primary dietary sources of clovamide-type compounds, has been consumed by Mesoamerican civilizations for over two millennia. The Olmec, Maya, and Aztec peoples prepared fermented beverages and foods from cacao beans, and Spanish colonial records from the 16th century document its use in Aztec medicine and ritual contexts. However, these historical uses were attributed to cacao as a whole food — the identification of N-coumaroyldopamine and N-caffeoyldopamine as specific bioactive constituents of cocoa only emerged in modern analytical chemistry. Similarly, red clover (Trifolium pratense), another source of clovamide-type compounds, has a documented history of use in European and North American folk medicine for respiratory and skin conditions, but again without any historical recognition of phenolamide content specifically.
Such as other N-phenylpropenoyl amino acids naturally occurring in cocoa, clovamide contributes to the astringent taste of unfermented cocoa beans as well as roasted cocoa nibs. The sensation induced by these amides in the oral cavity was described as mouth-drying and puckering astringent.
As a deliberately isolated or concentrated ingredient in dietary supplements, N-coumaroyldopamine is a modern development with no traditional medicine analog. The compound has attracted attention in recent years as a potential nutraceutical ingredient, particularly within the sports nutrition and wellness industries.
N-caffeoyldopamine and its natural analogs — N-cinnamoyldopamine, N-coumaroyldopamine, N-feruloyldopamine, and N-sinapoyldopamine — were synthesized and investigated to determine their potency as beta-adrenoceptor agonists, because they have chemical structural moieties found in beta-adrenoceptor agonists. These compounds form a closely related series of hydroxycinnamic acid amides that differ in the degree of hydroxylation and methoxylation on their cinnamic acid portion.
The structural features of N-coumaroyldopamine relevant to its biological activity include:
The parent phenolamide class has been described structurally: clovamide (N-caffeoyldopamine) is a derivative of caffeic acid (3,4-dihydroxycinnamic acid) and an amide isostere of rosmarinic acid. N-coumaroyldopamine differs from clovamide in that its cinnamic acid moiety is p-coumaric acid (one fewer catechol hydroxyl on the aromatic ring), making it somewhat less polar.
N-coumaroyldopamine and N-caffeoyldopamine were synthesized and purified as described previously (Park and Schoene, 2002; Park, 2005). The preparation method of N-coumaroyldopamine is usually obtained by esterification of dopamine with coumaric acid or its anhydride. The reaction is generally carried out under acidic conditions, and commonly used catalysts include sulfuric acid. In commercial supplement manufacturing, the compound may be extracted from plant sources (primarily cocoa or cacao-derived material) or produced synthetically.
The most studied and best-characterized mechanism of action for N-coumaroyldopamine is agonism at the beta-2 adrenergic receptor (β2AR). Among the compounds tested in one key study, N-coumaroyldopamine and N-caffeoyldopamine were the two most potent compounds, able to increase cyclic AMP (cAMP) at concentrations of less than 0.05 µM in U937 cells.
The decreasing order of potency was N-coumaroyldopamine > N-caffeoyldopamine > N-feruloyldopamine > N-sinapoyldopamine > N-cinnamoyldopamine.
Using beta2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta2-adrenoceptors in U937 cells. In producing cAMP in U937 cells, N-coumaroyldopamine and N-caffeoyldopamine were as potent as several well-known beta2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol).
The beta2-adrenergic receptor signaling cascade that N-coumaroyldopamine activates operates as follows: activation of the β2-receptor by β2-agonists causes the α-subunit of the associated Gs protein to dissociate and couple with adenylate cyclase, leading to enhanced production of cAMP and stimulation of PKA. Elevated intracellular cAMP is central to many of the downstream effects attributed to this compound.
A downstream consequence of beta2-receptor activation and cAMP elevation is modulation of platelet activation. N-coumaroyldopamine and N-caffeoyldopamine are clovamide-type phenylpropenoic acid amides found in Theobroma cacao. They were investigated to determine their effects on P-selectin expression and platelet–leukocyte interactions in vitro and in vivo models. At a concentration of 0.05 µM, they were able to inhibit P-selectin expression on platelets by 33% (P < 0.011) and 30% (P < 0.012), respectively.
The inhibition was partially blocked by beta2-adrenoceptor antagonists, suggesting that beta2 receptors are probably engaged in the inhibition.
N-caffeoyldopamine and N-coumaroyldopamine could also suppress platelet–leukocyte interactions in blood samples by 36% (P < 0.013) and 32% (P < 0.011), respectively, at the same concentration (0.05 µM).
The reference literature on clovamide and its derivatives points to their antioxidative, antiplatelet (antithrombotic), anti-inflammatory, and even anticancer action. The antioxidant properties are associated with the polyphenolic hydroxyl groups in the catechol and cinnamate portions of the molecule, which can donate hydrogen atoms to quench reactive oxygen species. Clovamide represents an interesting compound for its remarkable antioxidant activity; it was shown that clovamide has antiradical properties similar to rosmarinic acid and caffeic acid.
N-coumaroyldopamine is highly susceptible to metabolism by Catechol-O-Methyl-Transferase (COMT) due to its two meta-phenolic hydroxyl substituents. This enzymatic methylation of the catechol ring would be expected to substantially reduce or eliminate beta2 receptor binding affinity, as the intact catechol geometry is critical for receptor interaction.
N-coumaroyldopamine is a highly selective beta2 agonist only in its unmetabolized form. It is exceptionally vulnerable to multiple metabolic processes which makes its ability to actually reach systemic circulation highly unlikely. As a dopamine prodrug, N-coumaroyldopamine will likely also fall short. Successful dopamine prodrugs, like docarpamine, are generally designed to be resistant to COMT and Phase II metabolism, whereas N-coumaroyldopamine is vulnerable to both.
Bioavailability data on isolated N-coumaroyldopamine in humans are absent from the published literature. For the broader clovamide class: data on the bioavailability and metabolism of clovamide(s) are limited. Given the ample evidence on other low-molecular-weight polyphenols (including phenolic acids), it can be assumed that the maximal plasma levels of clovamides/their metabolites range from nanomoles to a few micromoles per liter. The intestinal permeability of rosmarinic acid, which has a significant structural similarity to clovamide, was established to attain less than 1% of its intake volume.
Evidence level: Preclinical (in vitro and animal); no human clinical trials identified.
The most substantiated area of research for N-coumaroyldopamine is its effects on platelet function and platelet–leukocyte interactions, which are pathophysiologically relevant to cardiovascular disease.
Park and Schoene (2006), in a study published in the Journal of Pharmacology and Experimental Therapeutics, investigated the effects of N-coumaroyldopamine and N-caffeoyldopamine on P-selectin expression and platelet–leukocyte interactions using both in vitro blood sample assays and an in vivo mouse model. N-coumaroyldopamine and N-caffeoyldopamine were investigated to determine their effects on P-selectin expression and platelet–leukocyte interactions in vitro and in vivo models. At a concentration of 0.05 µM, they were able to inhibit P-selectin expression on the platelets by 33% (P < 0.011) and 30% (P < 0.012), respectively. The inhibition was partially blocked by β2-adrenoceptor antagonists, suggesting that β2 receptors are probably engaged in the inhibition.
N-caffeoyldopamine and N-coumaroyldopamine could also suppress platelet–leukocyte interactions in blood samples by 36% (P < 0.013) and 32% (P < 0.011), respectively, at the same concentration (0.05 µM). In an animal study, mice administered orally with N-caffeoyldopamine (50 and 100 µg/35 g of body weight) also showed great reduction in the P-selectin expression and platelet–leukocyte interactions.
These data suggest that the clovamide-type phenylpropenoic acid amides are able to suppress platelet–leukocyte interactions via inhibiting P-selectin expression.
N-coumaroyldopamine inhibits platelet aggregation in vitro and in vivo through the reduction of thromboxane B2 production, the expression of P-selectin, the inhibition of platelet–leukocyte interactions and the increase in cAMP level in platelets. Since platelet aggregation plays a critical role in the pathogenesis of vascular disorders, these results indicate that N-coumaroyldopamine and its conjugates show potential application in protecting against the risk of cardiovascular disease.
Limitations: All cardiovascular evidence is derived from in vitro experiments and one small animal study. No randomized controlled trials, pharmacokinetic studies, or dose-finding studies in humans have been published. The concentrations used in vitro (around 0.05 µM) may not be achievable in plasma after oral ingestion given the compound's metabolic vulnerability.
Evidence level: In vitro only; no human studies identified.
The foundational study on N-coumaroyldopamine's pharmacological activity was published by Park (2005) in The FASEB Journal. N-caffeoyldopamine and its natural analogs (including N-coumaroyldopamine) were synthesized and investigated to determine their potency as beta-adrenoceptor agonists, because they have chemical structural moieties found in beta-adrenoceptor agonists. Among the compounds tested, N-coumaroyldopamine and N-caffeoyldopamine were the two most potent compounds, able to increase cAMP at concentrations < 0.05 µM in U937 cells.
The decreasing order of potency was N-coumaroyldopamine > N-caffeoyldopamine > N-feruloyldopamine > N-sinapoyldopamine > N-cinnamoyldopamine. Using beta2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta2-adrenoceptors in U937 cells.
In producing cAMP in U937 cells, N-coumaroyldopamine and N-caffeoyldopamine were as potent as several well-known beta2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol). These results indicate that N-coumaroyldopamine and N-caffeoyldopamine are potent compounds able to increase cAMP via beta2-adrenoceptors in U937 cells, and may have potential effects on human health.
Limitations: This study was conducted entirely in a myelocytic cell line (U937), a human leukemia cell line used as a model for monocyte/macrophage research. It does not constitute human clinical evidence. The U937 model does not replicate whole-body pharmacokinetics, oral bioavailability, first-pass metabolism, or tissue distribution. The compound has not been evaluated in bronchial, adipose, or skeletal muscle tissue — the tissues most relevant to beta2 receptor applications in sports nutrition contexts. No in vivo dose–response data in mammals were reported in this study.
Evidence level: In vitro; no human clinical trials identified.
The reference literature on clovamide and its derivatives points to their antioxidative, antiplatelet (antithrombotic), anti-inflammatory, and even anticancer action. These antioxidant effects are primarily attributed to the ability of the polyphenolic hydroxyl groups in the molecule to scavenge reactive oxygen species. Clovamide represents an interesting compound for its remarkable antioxidant activity; it was shown that clovamide has antiradical properties similar to rosmarinic acid and caffeic acid.
HCAAs have been implicated in oxidative stress defense in plants and utilized as a potential antioxidant and chemotherapeutic agent. This type of chemical is anti-inflammatory in human monocytes (clovamide) and mouse microglia (clovamide derivative) and neuroprotective in vitro, suggesting a potential to reduce chronic inflammatory responses.
Limitations: Antioxidant evidence for N-coumaroyldopamine specifically (as opposed to the broader clovamide class) is primarily in vitro. Direct human clinical antioxidant trials with isolated N-coumaroyldopamine have not been reported.
Evidence level: Primarily in vitro (cell culture); no human data.
In addition to possession of anti-oxidant properties, clovamide has recently been reported to have a neuroprotective effect in SH-SY5Y cells exposed to ischemic and excitotoxic injury. The SH-SY5Y cell line is a commonly used model of human neuroblastoma/dopaminergic neurons. The neuroprotective data here pertain primarily to clovamide (N-caffeoyldopamine) rather than to N-coumaroyldopamine directly, and the two compounds should not be conflated without direct comparative evidence.
Studies on the properties of clovamide and related compounds, their significance as bioactive components of the diet, as well as their effects on human health are a relatively new research trend. On the other hand, in vitro and in vivo evidence indicates the considerable potential of these substances in the context of maintaining human health or using them as pharmacophores.
Limitations: All neuroprotective evidence is in vitro and pertains to closely related but structurally distinct analogs (primarily clovamide/N-caffeoyldopamine). No animal or human data on neuroprotection for N-coumaroyldopamine itself have been identified in the peer-reviewed literature.
Evidence level: Theoretical/in vitro only; no human clinical evidence.
N-coumaroyldopamine has been marketed in sports nutrition supplements primarily on the basis of its in vitro beta2 receptor agonism. Beta2-adrenergic receptor activation in adipose tissue can theoretically stimulate lipolysis through cAMP-dependent pathways, and beta2 agonism in skeletal muscle has been associated with anabolic signaling in pharmacological contexts. Early laboratory research has suggested that N-coumaroyldopamine may promote cyclic AMP (cAMP) signaling, a pathway involved in energy metabolism and fat oxidation.
Some preliminary in vitro and animal studies indicate possible benefits for cardiovascular function and metabolic health, although these effects have not yet been confirmed in large-scale human clinical trials.
Limitations: No clinical trials in athletes or healthy adults have been conducted or published evaluating N-coumaroyldopamine for body composition, fat oxidation, or exercise performance. The rationale rests entirely on receptor pharmacology from a single cell line study combined with extrapolation from pharmaceutical beta2 agonists (e.g., clenbuterol, salbutamol). The metabolic vulnerability of the compound (see Pharmacokinetics section) substantially undermines the theoretical basis for oral administration producing meaningful beta2 agonist activity in vivo.
N-coumaroyldopamine is not the subject of an official pharmacopeial monograph, and no regulatory body (including NIH ODS, EMA, EFSA, or WHO) has established a recommended daily intake or tolerable upper limit for this compound.
In the published scientific literature, concentrations studied in vitro were in the sub-micromolar range: N-coumaroyldopamine and N-caffeoyldopamine were able to increase cAMP at concentrations less than 0.05 µM in U937 cells. At the concentration of 0.05 µM, they were able to inhibit P-selectin expression on platelets by 33%.
In the in vivo (mouse) component of the platelet study, mice administered orally with N-caffeoyldopamine (50 and 100 µg/35 g of body weight) also showed great reduction in P-selectin expression and platelet–leukocyte interactions by 31 to 45% (P < 0.011) and 34 to 43% (P < 0.014), respectively. These doses pertain to N-caffeoyldopamine, not N-coumaroyldopamine directly, and were administered in a mouse model. No human oral dosage has been established in any published peer-reviewed study for N-coumaroyldopamine.
In dietary supplement products, N-coumaroyldopamine is typically supplied as a standardized extract of cocoa or as a synthesized ingredient, most commonly at doses reported in product literature of 25–100 mg per serving. However, these commercial dosages have no peer-reviewed clinical basis and are not verifiable through authoritative scientific sources.
Despite a growing interest in the biological activity of natural polyphenolic substances, studies on the properties of clovamide and related compounds, their significance as bioactive components of the diet, as well as their effects on human health are a relatively new research trend. On the other hand, in vitro and in vivo evidence indicates the considerable potential of these substances in the context of maintaining human health or using them as pharmacophores. No dedicated human safety studies, tolerance studies, pharmacokinetic studies, or toxicology studies for isolated N-coumaroyldopamine have been identified in peer-reviewed sources. No regulatory authority has evaluated N-coumaroyldopamine's safety profile for use as a dietary supplement ingredient.
N-coumaroyldopamine is highly susceptible to metabolism by Catechol-O-Methyl-Transferase (COMT) due to its two meta-phenolic hydroxyl substituents. Individuals taking COMT inhibitors — a class of drugs used in Parkinson's disease management (e.g., entacapone, tolcapone) — might theoretically experience altered metabolism of N-coumaroyldopamine. However, this interaction has not been studied in any published research.
Given the compound's demonstrated in vitro beta2 receptor agonist activity, comparable in potency to well-known beta2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol) at the cellular level, there are theoretical cardiovascular safety implications. Beta2-adrenergic agonism, particularly at higher systemic levels, is associated with tachycardia, hypokalemia, tremor, and cardiac arrhythmia. Whether N-coumaroyldopamine can achieve therapeutically or toxicologically relevant systemic concentrations after oral ingestion remains unknown, given its COMT-mediated metabolic vulnerability.
N-coumaroyldopamine is structurally related to higenamine and other plant-based phenolic amides. Higenamine (norcoclaurine) is a beta-adrenergic agonist that the World Anti-Doping Agency (WADA) added to its Prohibited List in 2017. While N-coumaroyldopamine itself does not appear on the WADA Prohibited List as of available published sources, its structural and mechanistic similarity to higenamine may be relevant to athletes subject to anti-doping testing, particularly given the broader concern that compounds which could potentially be introduced into a supplement via use of a natural extract include compounds such as octopamine and higenamine.
Clovamides are characterized by a low threshold for perceptible astringent effects (concentrations > 10 µmol/L), and therefore their ingestion may evoke astringent effects in the mouth. This is a sensory, not toxicological, consideration, but relevant to dietary supplement formulation and tolerability.
No chronic toxicity data, reproductive toxicity data, genotoxicity evaluations, or carcinogenicity assessments have been published for N-coumaroyldopamine as an isolated ingredient. No maximum tolerated dose, NOAEL (No-Observed-Adverse-Effect Level), or acceptable daily intake has been established by any regulatory authority. The compound's oral bioavailability in humans remains entirely unstudied in clinical settings.
The totality of evidence for N-coumaroyldopamine as a bioactive ingredient rests on a small body of cell culture and animal experiments, primarily conducted by a single research group (Park and colleagues) and published in the period 2005–2006. The two most cited studies — one demonstrating beta2 receptor agonism in U937 cells, and one demonstrating suppression of P-selectin expression and platelet–leukocyte interactions in vitro and in mice — are methodologically sound within their models, but represent the lowest tiers of clinical evidence. No randomized controlled trials, prospective cohort studies, or systematic reviews specific to N-coumaroyldopamine have been published. Studies on the properties of clovamide and related compounds and their effects on human health are a relatively new research trend; in vitro and in vivo evidence indicates considerable potential of these substances as pharmacophores. Translation of these findings to human health outcomes, dosage recommendations, or safety profiles is not currently supported by the available evidence base.
Health conditions that N-coumaroyldopamine may help support.
Body systems that N-coumaroyldopamine may help support.
Go back